@article{oai:gunma-u.repo.nii.ac.jp:00009122,
 author = {Yudistiro, Ryan and Heryanto, Yusri Dwi and Kodaira, Sayaka and Higuchi, Tetsuya and Arisaka, Yukiko and Tokue, Azusa and Taketomi-Takahashi, Ayako and Tsukamoto, Norifumi and Yokohama, Akihiko and Handa, Hiroshi and Koiso, Hiromi and Ishizaki, Takuma and Tsushima, Yoshiko},
 issue = {3},
 journal = {The Kitakanto medical journal = 北関東医学},
 month = {Aug},
 note = {Journal Article, Background and Aims: Radioimmunotherapy (RIT) appears as one of the most effective treatment options for patientswith relapsed or resistant non-Hodgkin’s lymphoma (NHL).　Our aim was to evaluate the role of pre-RIT 18F-fluorodeoxyglucose-positron emission tomography╱computed tomography (FDG-PET╱CT) as an early predictor of 90Y-Ibritumomabtiuxetan treatment response.　Methods: We included consecutive 20 patients with relapsed NHL (10 males; meanage, 58.5 ± 8.9 years old) who were treated with 90Y-Ibritumomab tiuxetan.　FDG-PET╱CT was performed before andafter treatment.　Semiquantitative parameters of all measurable FDG-avid lesions were measured and averaged.　Ameasurable FDG-avid lesion was defined as a lesion that showed FDG uptake higher than liver with a diameter morethan 1 cm.　Treatment response was determined by visual assessment based on a five-point score criteria from FDGPET╱CT after treatment.　Results: Fourteen patients (70%) were classified as responders and the other six patients(30%) as non-responders.　All semiquantitative parameters except for MTV demonstrated significantly lower values inthe responders compared with the non-responders (p＜0.05).　Conclusions: Semiquantitative evaluation by SUVmax,SUVpeak, and TLG before treatment were useful as early predictors of 90Y-Ibritumomab tiuxetan treatment response.},
 pages = {151--156},
 title = {Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response},
 volume = {68},
 year = {2018}
}